Table 2.
Patient characteristics by vaccination status
| Unvaccinated (n=6175) | Two doses only (n=5394) | Three doses (n=5425) | Total (n=16 994) | p value* | ||
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age group | ||||||
| 18–49 years | 3133 (50·7%) | 2800 (51·9%) | 1386 (25·5%) | 7319 (43·1%) | <0·0001 | |
| 50–64 years | 1326 (21·5%) | 1090 (20·2%) | 1004 (18·5%) | 3420 (20·1%) | .. | |
| ≥65 years | 1716 (27·8%) | 1504 (27·9%) | 3035 (55·9%) | 6255 (36·8%) | .. | |
| Sex | ||||||
| Female | 3494 (56·6%) | 3284/5393 (60·9%)† | 3045 (56·1%) | 9823/16 993 (57·8%) | <0·0001 | |
| Male | 2681 (43·4%) | 2109/5393 (39·1%)† | 2380 (43·9%) | 7170/16 993 (42·2%) | .. | |
| Race and ethnicity | ||||||
| Non-Hispanic Asian or Pacific Islander | 301 (4·9%) | 445 (8·2%) | 691 (12·7%) | 1437 (8·5%) | <0·0001 | |
| Non-Hispanic Black | 996 (16·1%) | 738 (13·7%) | 517 (9·5%) | 2251 (13·2%) | .. | |
| Hispanic | 2666 (43·2%) | 2650 (49·1%) | 2068 (38·1%) | 7384 (43·5%) | .. | |
| Other or unknown | 254 (4·1%) | 213 (3·9%) | 185 (3·4%) | 652 (3·8%) | .. | |
| Non-Hispanic White | 1958 (31·7%) | 1348 (25·0%) | 1964 (36·2%) | 5270 (31·0%) | .. | |
| Body-mass index | ||||||
| Underweight (<18·5 kg/m2) | 181 (2·9%) | 147 (2·7%) | 166 (3·1%) | 494 (2·9%) | <0·0001 | |
| Normal or healthy weight (18·5–24·9 kg/m2) | 1421 (23·0%) | 1198 (22·2%) | 1398 (25·8%) | 4017 (23·6%) | .. | |
| Overweight (25·0–29·9 kg/m2) | 1646 (26·7%) | 1535 (28·5%) | 1616 (29·8%) | 4797 (28·2%) | .. | |
| Obese, class 1 (30·0–34·9 kg/m2) | 1388 (22·5%) | 1155 (21·4%) | 1153 (21·3%) | 3696 (21·7%) | .. | |
| Obese, class 2–3 (≥35·0 kg/m2) | 1440 (23·3%) | 1288 (23·9%) | 1076 (19·8%) | 3804 (22·4%) | .. | |
| Unknown | 99 (1·6%) | 71 (1·3%) | 16 (0·3%) | 186 (1·1%) | .. | |
| Comorbidities | ||||||
| Hypertension | 1921 (31·1%) | 1961 (36·4%) | 3036 (56·0%) | 6918 (40·7%) | <0·0001 | |
| Congestive heart failure | 525 (8·5%) | 633 (11·7%) | 1015 (18·7%) | 2173 (12·8%) | <0·0001 | |
| Myocardial infarction | 225 (3·6%) | 245 (4·5%) | 406 (7·5%) | 876 (5·2%) | <0·0001 | |
| Peripheral vascular disease | 1065 (17·2%) | 1113 (20·6%) | 2204 (40·6%) | 4382 (25·8%) | <0·0001 | |
| Cerebrovascular disease | 298 (4·8%) | 298 (5·5%) | 460 (8·5%) | 1056 (6·2%) | <0·0001 | |
| Diabetes status | ||||||
| Diabetes with unknown glycated haemoglobin | 111 (1·8%) | 70 (1·3%) | 69 (1·3%) | 250 (1·5%) | <0·0001 | |
| Diabetes with glycated haemoglobin <7·5% | 609 (9·9%) | 679 (12·6%) | 1214 (22·4%) | 2502 (14·7%) | .. | |
| Diabetes with glycated haemoglobin ≥7·5% | 539 (8·7%) | 551 (10·2%) | 681 (12·6%) | 1771 (10·4%) | .. | |
| Chronic obstructive pulmonary disease | 1142 (18·5%) | 1081 (20·0%) | 1594 (29·4%) | 3817 (22·5%) | <0·0001 | |
| Renal disease | 740 (12·0%) | 809 (15·0%) | 1399 (25·8%) | 2948 (17·3%) | <0·0001 | |
| Malignancy | 343 (5·6%) | 341 (6·3%) | 678 (12·5%) | 1362 (8·0%) | <0·0001 | |
| Organ transplant | 29 (0·5%) | 58 (1·1%) | 105 (1·9%) | 192 (1·1%) | <0·0001 | |
| Charlson Comorbidity Index | ||||||
| 0 | 3346 (54·2%) | 2665 (49·4%) | 1577 (29·1%) | 7588 (44·7%) | <0·0001 | |
| 1 | 1078 (17·5%) | 925 (17·1%) | 826 (15·2%) | 2829 (16·6%) | .. | |
| 2 | 481 (7·8%) | 459 (8·5%) | 663 (12·2%) | 1603 (9·4%) | .. | |
| 3 | 297 (4·8%) | 291 (5·4%) | 459 (8·5%) | 1047 (6·2%) | .. | |
| ≥4 | 973 (15·8%) | 1054 (19·5%) | 1900 (35·0%) | 3927 (23·1%) | .. | |
| Vaccine and infection history | ||||||
| Influenza vaccine in the year before admission | 1311 (21·2%) | 2651 (49·1%) | 4510 (83·1%) | 8472 (49·9%) | <0·0001 | |
| Pneumococcal vaccine in the 5 years before admission | 1050 (17·0%) | 1120 (20·8%) | 1607 (29·6%) | 3777 (22·2%) | <0·0001 | |
| Previous positive SARS-CoV-2 PCR test | 935 (15·1%) | 900 (16·7%) | 756 (13·9%) | 2591 (15·2%) | 0·0004 | |
Data are n (%) or n/N (%), unless otherwise specified.
*
χ2 test comparing unvaccinated, two vaccine doses, and three vaccine doses groups.
†
One patient had an unknown sex and was excluded.